newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
fintech/news//Bnn Bloomberg
Apotex expects to sell between 41.7 million and 50 million shares at a price between $20 and $24 per share.
Apotex Health Corp. plans to raise about $1 billion through an initial public offering.
KEY POINTS
Between 35.4 million and 42.5 million shares will be sold in a treasury offering worth $850 million.
A secondary offering will include 6.25 million to 7.5 million shares from existing shareholders, totaling $150 million.
Selling shareholders may grant underwriters an over-allotment option for up to 7.5 million extra shares.
TORONTO — Drug company Apotex Health Corp. says it is looking to sell about $1 billion worth of shares in its initial public offering.
The company says it expects to sell between 41.7 million and 50 million shares at a price between $20 and $24 per share.
The plan includes the sale of between 35.4 million and 42.5 million shares in a treasury offering by the company valued at a total of about $850 million.
It also includes a secondary offering of between 6.25 million and 7.5 million shares by certain shareholders valued at a total of about $150 million.
The selling shareholders are also expected to grant an over-allotment option to the underwriters for up to an additional 6.25 million to 7.5 million shares at the offering price
Apotex, which has applied to list the shares on the Toronto Stock Exchange, has a broad portfolio of generic drugs and consumer health products.
This report by The Canadian Press was first published June 1, 2026.
The Canadian Press